Form 4 for AMRX Amneal Pharmaceuticals, Inc.
Accepted 2023-03-03 00:00:00 ET · period of report 2023-03-01 · accession 0001209191-23-015516 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-03-03 | 2023-03-01 | AMRX | Konidaris Tasos | EVP, CFO | M - OptEx | — | +36.2K | 247.8K | +17% | — |
| D | 2023-03-03 | 2023-03-01 | AMRX | Konidaris Tasos | EVP, CFO | M - OptEx | $0.00 | -36.2K | 72.4K | -33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2023-03-01 | M | A | 36,197 | — | 247,832 | D | — | — | (F1) Represents shares of the Issuer's Class A Common Stock awarded to the reporting person in connection with the vesting of restricted stock units. (F2) Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. |
| 2 | Derivative | Restricted Stock Units | 2023-03-01 | M | D | 36,197 | $0.00 | 72,394 | D | — · — to — | 36,197 Class A Common Stock | (F2) Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. (F3) On March 1, 2021, the reporting person was granted 144,788 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. |